Valbenazine + Placebo oral capsule

ApprovedCompleted

2 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Tardive Dyskinesia (TD)

Conditions

Tardive Dyskinesia (TD)

Trial Timeline

Mar 18, 2019 → Jan 30, 2020

NCT ID

NCT03891862

About Valbenazine + Placebo oral capsule

Valbenazine + Placebo oral capsule is a approved stage product being developed by Neurocrine Biosciences for Tardive Dyskinesia (TD). The current trial status is completed. This product is registered under clinical trial identifier NCT03891862. Target conditions include Tardive Dyskinesia (TD).

What happened to similar drugs?

2 of 6 similar drugs in Tardive Dyskinesia (TD) were approved

Approved (2) Terminated (1) Active (4)

🔄levetiracetam + placeboUCBPhase 3

✅Valbenazine Oral CapsuleNeurocrine BiosciencesApproved

🔄NBI-98854Neurocrine BiosciencesPhase 3

🔄NBI-98854 + PlaceboNeurocrine BiosciencesPhase 3

🔄ValbenazineNeurocrine BiosciencesPhase 3

✅Valbenazine + Placebo oral capsuleNeurocrine BiosciencesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03891862	Approved	Completed	Mar 18, 2019	Jan 30, 2020	Tardive Dyskinesia (TD)
NCT03698331	Approved	Completed	Sep 14, 2018	Apr 3, 2019	Tardive Dyskinesia (TD)
NCT03530293	Phase 2	Terminated	Apr 17, 2018	Jul 16, 2019	Tourette Syndrome
NCT03325010	Phase 2	Completed	Oct 5, 2017	Nov 16, 2018	Tourette Syndrome

Competing Products

13 competing products in Tardive Dyskinesia (TD)

See all competitors

Product	Company	Stage	Hype Score
Sarizotan	Merck	Pre-clinical	18
levetiracetam + placebo	UCB	Phase 3	40
Valbenazine	Neurocrine Biosciences	Phase 1	18
Valbenazine Oral Capsule	Neurocrine Biosciences	Approved	32
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
NBI-98854	Neurocrine Biosciences	Phase 3	37
NBI-98854	Neurocrine Biosciences	Phase 2	32
NBI-98854 + Placebo	Neurocrine Biosciences	Phase 3	37
Valbenazine	Neurocrine Biosciences	Phase 3	37
NBI-98854 + NBI-98854 + Placebo	Neurocrine Biosciences	Phase 2	32
Valbenazine + Placebo oral capsule	Neurocrine Biosciences	Approved	40
NBI-1065890 + Placebo	Neurocrine Biosciences	Phase 2	39